EXHIBIT 99

CardioDynamics Co-Sponsors Inaugural International Acute Heart Failure
Meeting

    SAN DIEGO--(BUSINESS WIRE)--April 22, 2004--

     Company Participation in Seven Upcoming National Conferences
            Offers ICG Education to over 30,000 Clinicians

    CardioDynamics (Nasdaq:CDIC), the innovator and leader of
Impedance Cardiography (ICG) technology, today announced its
co-sponsorship of the First International Acute Heart Failure
Syndromes Meeting taking place in Cannes, France on May 1-2, 2004.
Other co-sponsors of the meeting include Abbott Laboratories, Amgen,
GlaxoSmithKline, Medtronic Inc., and Pfizer Inc. The meeting will
bring together academic, industry and government leaders to
comprehensively examine the growing clinical problem of
hospitalizations of heart failure patients. In addition to reviewing
new pharmacological, pacing, and surgical therapies, attendees will
discuss methodologies for diagnostic evaluation of patients admitted
with heart failure, including noninvasive hemodynamics, biomarkers,
nuclear imaging, and magnetic resonance imaging.
    "Heart disease has no geographic, gender, or socioeconomic
boundaries -- nearly 17 million people around the world die of
cardiovascular disease each year," stated Michael K. Perry, chief
executive officer of CardioDynamics. "This conference will broaden
international understanding of ICG applications in the diagnosis and
treatment of heart failure patients. Our ICG technology is currently
available in 49 countries and is assisting clinicians in fundamentally
changing the way cardiovascular medicine is practiced. We have largely
focused our efforts in the domestic market with international sales
representing approximately five percent of total revenue. As part of
our continued growth initiatives, we will look to further increase our
presence abroad."
    The company also announced it will be exhibiting its ICG BioZ
systems at seven U.S. medical meetings during April and May 2004,
including the American College of Physicians -- American Society of
Internal Medicine in New Orleans, April 21-24; the International
Society for Heart and Lung Transplant meeting in San Francisco, April
21-24; the National Teaching Institute -- American Association of
Critical Care Nurses in Orlando, May 18-20; the American Society of
Hypertension meeting in New York, May 19-21; and the North American
Society for Pacing & Electrophysiology in San Francisco, May 20-22.
    Perry added, "Our participation in key domestic and international
medical meetings is fundamental to fulfilling our mission and making
ICG's clinical value widely known. Medical conferences allow
physicians to become educated on the latest in technology and
treatment programs available. Our exhibits and clinical presentations
on ICG technology consistently demonstrate the significant role our
ICG technology plays in cardiac medicine."

    About CardioDynamics

    CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator
and leader of breakthrough medical technology called Impedance
Cardiography (ICG). The company's BioZ Systems are being used by
leading physicians around the world to help battle the number one
killer of men and women -- cardiovascular disease. Partners include GE
Healthcare and Philips Medical Systems. The worldwide market potential
for BioZ products is estimated to be $5 billion and an additional $800
million in recurring annual revenue for sensors. For additional
information or to request an investor package, refer to the company's
Web site at www.cdic.com.

    Forward-Looking (Safe Harbor) Statement

    Except for the historical and factual information contained
herein, this press release contains forward-looking statements, such
as market size, potential, growth, penetration rates, and
international presence the accuracy of which is necessarily subject to
uncertainties and risks including the company's sole dependence on the
BioZ product line, and various uncertainties characteristic of early
growth companies, as well as other risks detailed in the company's
filings with the SEC, including its 2003 Form 10-K. The company does
not undertake to update the disclosures contained in this press
release.

    CONTACT: CardioDynamics
             Investor Relations:
             Bonnie Ortega, 800-778-4825, ext. 1005
             bonnie@cdic.com
                or
             Media Relations:
             Irene Paigah, 800-778-4825, ext. 1012
             ip@cdic.com